Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma
NCT00478062Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2007
- Primary completion
- Jun 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GM-K562 in Hodgkin lymphoma (HL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Apr 2007; status: terminated.
02
Drugs
GM-K562
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00478062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478062.